JP2017519008A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519008A5
JP2017519008A5 JP2016572697A JP2016572697A JP2017519008A5 JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5
Authority
JP
Japan
Prior art keywords
serelaxin
pharmaceutical formulation
patient
biological sample
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572697A
Other languages
English (en)
Japanese (ja)
Other versions
JP6820748B2 (ja
JP2017519008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054399 external-priority patent/WO2015189790A1/en
Publication of JP2017519008A publication Critical patent/JP2017519008A/ja
Publication of JP2017519008A5 publication Critical patent/JP2017519008A5/ja
Application granted granted Critical
Publication of JP6820748B2 publication Critical patent/JP6820748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016572697A 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用 Expired - Fee Related JP6820748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (3)

Publication Number Publication Date
JP2017519008A JP2017519008A (ja) 2017-07-13
JP2017519008A5 true JP2017519008A5 (https=) 2018-07-19
JP6820748B2 JP6820748B2 (ja) 2021-01-27

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572697A Expired - Fee Related JP6820748B2 (ja) 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用

Country Status (11)

Country Link
US (2) US20170100460A1 (https=)
EP (1) EP3154559B1 (https=)
JP (1) JP6820748B2 (https=)
KR (1) KR20170018829A (https=)
CN (1) CN106413740A (https=)
AU (2) AU2015273097A1 (https=)
BR (1) BR112016028833A2 (https=)
CA (1) CA2952061A1 (https=)
MX (1) MX2016016414A (https=)
RU (1) RU2016147122A (https=)
WO (1) WO2015189790A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
ES2902533T3 (es) 2013-11-21 2022-03-28 Brigham & Womens Hospital Inc Composiciones y métodos para tratar la hipertensión pulmonar
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
JP7537431B2 (ja) * 2019-06-20 2024-08-21 ソニーグループ株式会社 情報処理装置、情報処理方法、及びプログラム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000914A (es) * 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
EP1995596B1 (en) * 2007-05-24 2011-12-14 F. Hoffmann-La Roche AG Methods for assessing heart failure in patients with atrial fibrillation using GDF-15
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение

Similar Documents

Publication Publication Date Title
JP2017519008A5 (https=)
Myles et al. Importance of intraoperative oliguria during major abdominal surgery: findings of the restrictive versus liberal fluid therapy in major abdominal surgery trial
Guo et al. Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1–mediated neutrophilic acute lung inflammation
Ingenbleek et al. Plasma transthyretin as a biomarker of lean body mass and catabolic states
Mondal et al. Stress hyperglycemia ratio, rather than admission blood glucose, predicts in-hospital mortality and adverse outcomes in moderate-to severe COVID-19 patients, irrespective of pre-existing glycemic status
Yanishi et al. Factors associated with the development of sarcopenia in kidney transplant recipients
Grodin et al. Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF
Behr The diagnosis and treatment of idiopathic pulmonary fibrosis
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
JP2016520573A5 (https=)
Zhang et al. The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism
Lin et al. Preliminary prospective study to assess the effect of early blood urea nitrogen/creatinine ratio-based hydration therapy on poststroke infection rate and length of stay in acute ischemic stroke
Lazzeri et al. Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization
Nazim et al. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes
de Almeida Faro et al. Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia
Sato et al. Therapeutic targets and early stage clinical trials for pulmonary fibrosis
Gores et al. Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy
Sharma et al. Alveolar macrophage activation in obese patients with obstructive sleep apnea
Csobay-Novák et al. Decreased plasma nociceptin/orphanin FQ levels after acute coronary syndromes
Rouini et al. Oral substitution of melatonin in critical care: a pharmacokinetic study in patients with intracranial hemorrhage
Kaman et al. Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support
Yamaguchi et al. A case of severe hypothyroidism causing cardiac tamponade associated with lithium intoxication
Stojković et al. The effect of stress induced-hyperglycemia on hospital treatment outcome in patients with acute myocardial infarction with st segment elevation
Shinohara et al. Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance